Oraya Therapeutics

January 23, 2015 | Eyewire Today

The UK’s Leading Blindness Organizations Come Together at House of Commons to Call for Better Funding, Screening, and Treatment for Macular Degeneration. >> More

October 6, 2014 | Mail Online: Health

Painless X-ray that can save failing eyes in 15 minutes. >> More

October 1, 2014 | Fierce Medical Devices

Oraya Therapetics Named Among Fierce Medical Devices 2014 Fierce 15. >> More

September 21, 2014 | Retinal Physician eUpdate

NTREPID Study of Oraya Therapy Continues to Show Favorable Safety Profile. >> More

September 14, 2014 | Eyewire Today

Three-Year Data from Oraya Therapeutics’ INTREPID Study Continue to Show Favorable Safety Profile of Non-Invasive Wet AMD Therapy. >> More

May 29, 2014 | San Francisco Business Times

Oraya Therapeutics named to San Francisco Business Times I-List — the 40-most innovative life science companies in the Bay Area. >> More

November 13, 2013 | Medical Device Daily

Oraya prepares for European rollout of IRay for wet AMD. >> More

November 7, 2013 | San Francisco Business Times

East Bay connection: Oraya, OnCore partnership a lesson in medical manufacturing. >> More

November 4, 2013 | MedCity News

Healthcare startup with noninvasive, one-time wet AMD treatments touts two years of success. >> More

October 2013 | Retina Today

Intrepid Study Demonstrates 2-Year Safety, Efficacy of Oraya Therapy. >> More

October 2, 2013 | eyewireTV Weekly

Two-year results of Oraya Therapeutics’ INTREPID study are presented, showing that radiation therapy for wet AMD is safe and effective. >> More

September 2013 | The Ophthalmologist

An Intrepid Assault on AMD >> More

September, 25 2013 | eyewireToday

Oraya Therapeutics INTREPID Study Demonstrates 2-year Safety and Effectiveness of Non-invasive Therapy for Wet AMD >> More

September 2013 | EUROTIMES SEMINAR SUPPLEMENT

Oraya Therapy – A Significant Advance in the Treatment of Wet AMD >> More

September 30, 2013 | CHOICE

X-ray Aid For Eyes >> More

September 30, 2013 | Readers Digest

This Won’t Hurt A Bit >> More

June/July, 2013 | Vision Magazine, Issue 60

Radiotherapy breakthrough to treat wet AMD >> More

April 18, 2013 | The Wall Street Journal

Oraya Therapeutics’ INTREPID Study Published in Ophthalmology, the Official Journal of the American Academy of Ophthalmology >> More

April 1, 2013 | New Retina MD

Radiation Therapy for Neovascular Age-related Macular Degeneration >> More

March 4, 2013 | Mail Online

The X-ray beam that could end painful jabs for ageing eyes >> More

March 1, 2013 | Ophthalmology Times

INTREPID identifies ‘best responders’: Fewer anti-VEGF injections among benefits of stereotactic radiotherapy for wet AMD >> More

February 27, 2013 | Insight Radio

Revolutionary Treatment for AMD Launched >> More

February 26, 2013 | Yahoo!7 News

Hope for eye disease sufferers >> More

Feb 25, 2013 | ITV

New hope for macular degeneration >> More

February 11, 2013 | SMT Online

OnCore Opens Medical Center-of-Excellence >> More

December 22, 2012 | Mail Online

Revolutionary X-ray treatment offers hope for diseased eyes >> More

November 28, 2012 | AZoRobtics

Non-Invasive Robotic Device Delivers Radiotherapy for Eye Disease >> More

November 20, 2012 | The Telegraph

Macular degeneration: new hope for elderly victims of disease that causes blindness. Nick Collins, Science Correspondent >> More

October 25, 2012 | Ocular Surgery News

Noninvasive radiotherapy reduces need for repeated anti-VEGF injections in AMD >> More

October 1, 2012 | Retina Today

Stereotatic Radiotherapy: Results of the INTREPID Study. Timothy L. Jackson, PhD, FRCOphth >> More

Back To Top

The INTREPID Trial of Stereotactic Radiosurgery for Choroidal Neovascularization
in AMD
- Peter K. Kaiser, M.D.
© 2015 All rights reserved. Oraya Therapeutics, Inc. The IRay® is a CE-marked medical device. The IRay is not available for sale in the United States. For additional details, including safety and risk information, please see the ORAYA THERAPY section of this website. Oraya, Oraya Therapy, IRay and I-Guide are either trademarks or registered trademarks of Oraya Therapeutics, Inc. in the United States and other countries.